Multiple Myeloma

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    CD38 Overexpression 100 Daratumumab (anti-CD38 monoclonal antibody):
    • Phase 2 trial daratumumab monotherapy: ORR 29%, PFS 3.7 mo (1)
    • Phase 3 trial daratumumab, lenalidomide, dexamethasone (PFS, not reached) vs. lenalidomide, dexamethasone (PFS 18.4 mo) (mo2)
    • Phase 3 trial daratumumab, bortezomib, dexamethasone (12-mo PFS 77.5%) vs. bortezomib, dexamethasone (12-mo PFS 29.4%) (3)
    • Phase 2 trial daratumumab, pomalidomide, and dexamethasone: ORR 60%, mPFS 8.8 mo, mOS 17.5 mo (4)*
    Isatuximab (anti-CD38 monoclonal antibody):
    • Phase 2 trial isatuximab monotherapy: ORR 4% (5)
    Other topics in Targets by Organ Site